Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
31.12
-1.00 (-3.11%)
At close: Mar 28, 2025, 4:00 PM
31.19
+0.07 (0.22%)
After-hours: Mar 28, 2025, 7:59 PM EDT

Company Description

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.

It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis.

It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.

The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.

Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.
Moderna logo
Country United States
Founded 2010
IPO Date Dec 7, 2018
Industry Biotechnology
Sector Healthcare
Employees 5,800
CEO Stephane Bancel

Contact Details

Address:
325 Binney Street
Cambridge, Massachusetts 02142
United States
Phone 617 714 6500
Website modernatx.com

Stock Details

Ticker Symbol MRNA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001682852
CUSIP Number 60770K107
ISIN Number US60770K1079
Employer ID 81-3467528
SIC Code 2836

Key Executives

Name Position
Stephane Bancel Chief Executive Officer and Director
Dr. Stephen Hoge M.D. President
James M. Mock Chief Financial Officer
Shannon Thyme Klinger J.D. Chief Legal Officer and Corporate Secretary
Dr. Jerh Collins Ph.D. Chief Technical Operations and Quality Officer
Lavina Talukdar CFA Senior Vice President and Head of Investor Relations
Colleen Hussey Senior Director of Corporate Communications
Tracey Franklin Chief People and Digital Technology Officer
Dr. Melanie Ivarsson M.B.A., Ph.D. Chief Development Officer
Dave Johnson Chief Data and AI Officer

Latest SEC Filings

Date Type Title
Mar 11, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 11, 2025 DEF 14A Other definitive proxy statements
Mar 11, 2025 ARS Filing
Feb 21, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 21, 2025 10-K Annual Report
Feb 14, 2025 8-K Current Report
Feb 12, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Dec 9, 2024 144 Filing
Dec 3, 2024 144 Filing